China’s nicotinamide mononucleotide (NMN) supplier EffePharm had embarked on its first human clinical trial as it seeked to validate the anti-ageing effects and safety of its ingredient “Uthever”.
NMN is an intermediate compound of nicotinamide adenine dinucleotide (NAD+). A low NAD+ level is linked to the onset of age-related diseases, including Alzheimer’s disease.
The trial would take place in different parts of the world and will measure two specific outcomes, namely 1) whether NMN intake increases the NAD+ level in blood serum and 2) its impact on body stamina through a walking endurance test.
“Besides measuring the NAD+ index from blood serum, we have added exercise performance as another outcome measure. The purpose is to see whether the body stamina will be improved,” scientific affairs director, Hank Hwang told NutraIngredients-Asia.